相关实验视频
Updated: Jun 30, 2026
10:50
Primary Culture of Human Vestibular Schwannomas
Published on: July 20, 2014
13.0K
主要肝硬瘤:病例报告和文献综述
Nguyen Thi Khuyen1, Truong Quoc Thanh2, Hoang Van Trung3
1Center for Pathology and Molecular Biology, K Hospital, Ha Noi, Vietnam.
Clinical medicine insights. Case reports
|December 11, 2023
概括
主要肝 schwannoma,一种罕见的肝脏瘤,具有挑战性的进行手术前诊断. 这项研究详细介绍了19例病例,突出了其独特的组织病理学和免疫组织化学特征,以准确诊断和切除后的良好预后.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 病理学 病理学 病理学
背景情况:
- 初级肝 schwannoma 是一个非常罕见的肝脏新生体.
- 术前诊断往往是困难的,因为非特异性症状和瘤稀有性.
研究的目的:
- 报告一个初级肝 schwannoma 的病例被误诊为恶性肝脏瘤.
- 为了记录19例初级肝 schwannoma 病例的临床和组织病理学特征.
- 强调诊断标准,以区分肝 schwannoma 和其他肝脏恶性瘤.
主要方法:
- 一个56岁的男性被误诊患有恶性肝脏瘤的案例报告.
- 从19名原发性肝 schwannoma 患者的临床和组织病理学数据的回顾性分析.
- 对S-100,CD34,CD117和SMA进行免疫组织化学染色.
主要成果:
- 该研究包括19名患者 (平均年龄为56.4岁),女性患病率更高.
- 瘤表现出典型的 schwannoma 组织学 (安东尼 A/B 区域) 和强大的 S-100 阳性.
- 所有患者都经历了完全切除,结果良好,在随访期间 (6-27个月) 没有出现复发.
结论:
- 初级肝 schwannoma 是一种罕见的瘤,在彻底切除术后预后良好.
- 组织病理学特征和S-100免疫组织化学是区分它与恶性肝脏瘤的关键.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...